Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0018681 (headache)
 56,091 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

This multicentre, double-blind, randomized, placebo-controlled, parallel study was designed to evaluate the efficacy of combined oral lysine acetylsalicylate and metoclopramide (LAS-MCP) in the acute treatment of migraine attacks. A total of 266 patients, 18-65 years old, with two to six attacks of migraine with or without aura (IHS criteria) per month were included. The patients had to treat two migraine attacks with LAS-MCP (1620 mg lysine acetylsalicylate--the equivalent of 900 mg aspirin--combined with 10 mg metoclopramide) or placebo. The main outcome measure was headache relief (reduction in headache severity from grade 3 or 2--severe or moderate--to grade 1 or 0--mild or none) 2 h after treatment. LAS-MCP was superior to placebo for headache relief (56% vs 28%) and for the following secondary outcome measures: complete headache relief (18% vs 7%; p < 0.001), nausea (28% vs 44%; p < 0.001), vomiting (3% vs 11%; p = 0.001), use of rescue medication (47% vs 68%; p < 0.001), global efficacy judged as good or excellent (32% vs 14%; p < 0.001). The tolerability was considered as good in 94% of treated attacks in both groups. Combined oral lysine acetylsalicylate and metoclopramide is an effective and well-tolerated acute treatment of migraine attacks.
Cephalalgia 1994 Aug
PMID:Combined oral lysine acetylsalicylate and metoclopramide in the acute treatment of migraine: a multicentre double-blind placebo-controlled study. 795 60

A combination of lysine acetylsalicylate (equivalent to 900 mg aspirin) and 10 mg metoclopramide (LAS + MTC) was compared with oral sumatriptan (100 mg) and placebo in 421 patients with migraine in a randomized, double-blind, clinical trial. LAS + MTC was as effective as sumatriptan with a decrease in headache from severe or moderate to mild or none in 57% and 53%, respectively, for the first migraine attack treated, the primary efficacy parameter. Both treatments were better than placebo (success rate 24%, p < 0.001). LAS + MTC was better tolerated than sumatriptan (adverse events in 18% and 28%, respectively, p < 0.05).
 ...
PMID:[The combination of oral lysine-acetylsalicylate and metoclopramide compared with oral sumatriptan in the treatment of migraine attacks. A randomized, double-blind, placebo-controlled clinical trial]. 899 78

Migraine is a common medical condition affecting more than 10% of population in Poland. Acute migraine attacks are often associated with gastrointestinal symptoms ranging from mild nausea to vomiting. The present study was specifically designed to compare the efficacy of the combination of lysine acetylsalicylate and metoclopramide (1620 mg LAS + 10 mg MTC--Migpriv) and ergotamine plus caffeine (2 mg ERG + 200 mg CAF--Coffecorn forte) in the treatment of migraine headache and nausea. 98 patients with migraine meeting HIS criteria were randomized. The primary endpoint was the number of patients having headache relief and no nausea or vomiting two hours after the drug intake. Significantly more Migpriv treated patients than Coffecorn ones were free of headache two hours after drug administration (58.7% vs. 35.7% respectively: p<0.002). Reported adverse events were rare and transient. Migpriv was significantly more effective than Coffecorn forte in relieving the migraine attack symptoms.
 ...
PMID:[Comparison of the effectiveness of lysine acetylsalicylate and metoclopramide combination with ergotamine plus caffeine in the treatment of migraine attacks]. 1530 20

Almotriptan (LAS 31416) is a new, oral, specific 5-hydroxytryptamine(1B/1D) receptor agonist for the treatment of migraine. The pharmacokinetics and safety of a range of oral doses were assessed in 23 healthy male volunteers. Peak plasma concentrations were reached between 1.5 and 4 h after dosing. The maximum plasma concentration and area under the curve showed dose proportionality over the dose range 5-200 mg. The elimination half-life was constant at approximately 3 h across all dose levels. A substantial proportion of the initial dose was excreted in urine (27%-39%) during 12 h post-dose and the main excretory product was unchanged drug. Three major urinary metabolites were detected, all of which were pharmacologically inactive. The most common events following almotriptan administration were headache, tiredness and mild nausea. Nine events (18%) were classed as probably related to almotriptan and these were all at the highest dose level of 200 mg. The maximum tolerated dose of almotriptan was, therefore, determined as 150 mg. In conclusion, almotriptan is well tolerated following single, oral doses up to 150 mg and has predictable pharmacokinetics.
 ...
PMID:Pharmacokinetics and safety of oral almotriptan in healthy male volunteers. 1538 81

Migraine is a common medical condition affecting nearly 10% of population in Poland. The aim of the study was to evaluate the efficacy, tolerability and safety of migraine abortive treatment with the combination of lysine acetylsalicylate and metoclopramide (1620 mg LAS + 10 mg MTC--Migpriv). 1620 patients with migraine, meeting International Headache Society (IHS) criteria were included in the study. The aim of the study was also determination of the number of patients having headache relief and no nausea or vomiting two hours after the drug intake. In most patients the migraine symptoms disappeared after a single dose administration. Reported adverse events were rare and short lasting. The study showed that metoclopramide was well tolerated and effective at relieving migraine attack symptoms.
 ...
PMID:[Assessment of efficacy of migraine attack treatment with lysine acetylsalicylate and metoclopramide]. 1577 Nov 35